4-Methyl-3,5,6,7,8,9,10,10a-octahydrocycloocta[d]pyridazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-Methyl-3,5,6,7,8,9,10,10a-octahydrocycloocta[d]pyridazine
• 英文别名: 4-methyl-3,5,6,7,8,9,10,10a-octahydrocycloocta[d]pyridazine
• 化学式: C₁₁H₁₈N₂
• 分子量: 178.27
• InChiKey: ORVASXSZVSRSAQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  24.4
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS
  申请人：ImmunoGen, Inc.

  公开号：EP2961435B1

  公开（公告）日：2019-05-01
• CONJUGATES COMPRISING CELL-BINDING AGENTS AND MAYTANSINOIDS AS CYTOTOXIC AGENTS
  申请人：IMMUNOGEN, INC.

  公开号：US20150359903A1

  公开（公告）日：2015-12-17

  The invention provides linker compounds containing a disulfide group, and maytansin-derived cytotoxic compounds that are useful for forming a CBA-drug conjugates, and conjugates so formed. Such conjugates and/or cytotoxic compounds may be effective for treating a range of diseases, such as cancer, with a relatively high activity at a relatively low, non-toxic dose.
• MODIFIED IL-2 POLYPEPTIDES AND USES THEREOF
  申请人：Bright Peak Therapeutics AG

  公开号：US20210252157A1

  公开（公告）日：2021-08-19

  The present disclosure relates to modified IL-2 polypeptides, compositions comprising modified IL-2 polypeptides, methods of making the same, and methods of using the modified IL-2 polypeptides for treatment of diseases. In one aspect, the disclosure relates to the treatment of cancer using the modified IL-2 polypeptides. In some embodiments, the disclosed IL-2 polypeptides exhibit preferential binding characteristics to IL-2 receptor βγ complex (IL-2Rβ) over IL-2 receptor αβγ complex (IL-2Rα). In some embodiments, the molecular weight distribution of the modified IL-2 polypeptides is monodispersed.
• US9999680B2
  申请人：——

  公开号：US9999680B2

  公开（公告）日：2018-06-19
• [EN] CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS<br/>[FR] CONJUGUÉS COMPRENANT DES AGENTS DE LIAISON CELLULAIRE (CBA) ET DES AGENTS CYTOTOXIQUES
  申请人：IMMUNOGEN INC

  公开号：WO2014134457A2

  公开（公告）日：2014-09-04

  The invention provides linker compounds and cytotoxic compounds that are useful for forming a CBA-drug conjugate and conjugates so formed. Such conjugates and/or cytotoxic compounds may be effective for treating a range of diseases, such as cancer, with a relatively high activity at a relatively low, non-toxic dose.